法匹拉韦致1例COVID - 19患者弥散性红斑药疹

IF 1.1 Q4 ALLERGY

Journal of Cutaneous Immunology and Allergy Pub Date : 2023-08-07 DOI:10.1002/cia2.12321

Aki Honda MD, Toshiyuki Yamamoto MD, PhD

{"title":"法匹拉韦致1例COVID - 19患者弥散性红斑药疹","authors":"Aki Honda MD, Toshiyuki Yamamoto MD, PhD","doi":"10.1002/cia2.12321","DOIUrl":null,"url":null,"abstract":"<p>The case of a widespread erythematous drug eruption brought on by favipiravir is described here. Patch tests and the drug lymphocyte transformation test (LTT) both indicated a positive reaction. Since COVID-19 patients take many medications, the potential for a drug eruption must be taken into account when diagnosing a rash.\n <figure>\n <div><picture>\n <source></source></picture><p></p>\n </div>\n </figure></p>","PeriodicalId":15543,"journal":{"name":"Journal of Cutaneous Immunology and Allergy","volume":null,"pages":null},"PeriodicalIF":1.1000,"publicationDate":"2023-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cia2.12321","citationCount":"1","resultStr":"{\"title\":\"A case of disseminated erythematous drug eruption caused by favipiravir in a patient with COVID-19\",\"authors\":\"Aki Honda MD, Toshiyuki Yamamoto MD, PhD\",\"doi\":\"10.1002/cia2.12321\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>The case of a widespread erythematous drug eruption brought on by favipiravir is described here. Patch tests and the drug lymphocyte transformation test (LTT) both indicated a positive reaction. Since COVID-19 patients take many medications, the potential for a drug eruption must be taken into account when diagnosing a rash.\\n <figure>\\n <div><picture>\\n <source></source></picture><p></p>\\n </div>\\n </figure></p>\",\"PeriodicalId\":15543,\"journal\":{\"name\":\"Journal of Cutaneous Immunology and Allergy\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.1000,\"publicationDate\":\"2023-08-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cia2.12321\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Cutaneous Immunology and Allergy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/cia2.12321\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ALLERGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cutaneous Immunology and Allergy","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cia2.12321","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ALLERGY","Score":null,"Total":0}

引用次数: 1

摘要

Favipiravir是一种RNA依赖的RNA聚合酶抑制剂，是一种用于治疗新型或复发性流感感染的药物，也用于治疗目前在全球肆虐的COVID- 19。我们在此报告一例弥散性红斑性药疹，由药物诱导淋巴细胞转化试验(LTT)和斑贴试验结果诊断。42岁日本女性，既往无药疹史，因COVID- 19所致肺炎和肝功能障碍入住呼吸内科，开始使用法匹拉韦治疗。患者在服药后12天(感染发生后第19天)出现发痒疹后转介至我科。首次就诊时，患者出现斑疹样丘疹，全身及面部无黏膜病变(图1)。实验室检查结果:天冬氨酸转氨酶31 U/L(正常范围13 - 30 U/L)，丙氨酸转氨酶64 U/L (7 - 23 U/L)，乳酸脱氢酶260 U/L (124 - 222 U/L)， C反应蛋白2.92 mg/dL (0.3 mg/dL)。考虑到病毒毒性疹或药物疹，我们在入院后停止所有口服药物，并开始口服抗过敏药物。在皮疹和感染愈合后，进行斑贴试验

本文章由计算机程序翻译，如有差异，请以英文原文为准。

A case of disseminated erythematous drug eruption caused by favipiravir in a patient with COVID-19

查看原文本刊更多论文

A case of disseminated erythematous drug eruption caused by favipiravir in a patient with COVID-19

The case of a widespread erythematous drug eruption brought on by favipiravir is described here. Patch tests and the drug lymphocyte transformation test (LTT) both indicated a positive reaction. Since COVID-19 patients take many medications, the potential for a drug eruption must be taken into account when diagnosing a rash.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Cutaneous Immunology and Allergy Medicine-Dermatology

CiteScore

0.60

自引率

10.00%

发文量

审稿时长

12 weeks